Drug Research
Lonza Partners with Cryoport and Strengthens its Vein-to-vein Delivery Network in Cell & Gene Therapy
Lonza and Cryoport, Inc announced their partnership in the cell and gene therapy field and across Lonza's 'vein-to-vein' delivery network. As a part of this commitment, Lonza announced Cryoport as its preferred partner in the transport and delivery of...
Drug Research
A2 Biotherapeutics emerges from Stealth Mode to develop tumour cell therapeutics
A2 Biotherapeutics, a biotechnology company developing innovative cell therapies for cancer patients, announced its official launch. The company, founded in 2018 by veteran biotechnology leaders, has a unique and potentially broad solution for the central problem of cancer research...
Drug Research
CDMOs to benefit from rising BTDs, orphan drugs and fast track status
CPhI Worldwide โ the worldโs largest pharma event taking place in Frankfurt (5th โ 7th November 2019) โ has released the fourth part of its eponymous 2019 annual Report. Experts Peter Soelkner, Managing Director, Vetter Pharma International GmbH, Stewart...
Drug Research
Bioeq announces Coherus as marketing and distribution partner for its biosimilar to Lucentis in the U.S.
Zรผrich, Switzerland. Bioeq IP AG has announced that it signed a license and development agreement with Coherus BioSciences, Inc. , under which Coherus will exclusively market and distribute Bioeqโs biosimilar candidate to Lucentis in the United States (U.S.).
Bioeq will...
Drug Research
Sygnature Discovery invests in high-throughput screening capability
Sygnature Discovery has added in-house high-throughput screening (HTS) to its range of drug discovery services. This is backed up by its new Leadfinder compound library.
HTS allows many thousands of molecules to be tested for activity in a short period...
Drug Research
BD Launches innovative two-step disposable autoinjector
Becton, Dickinson and Company (BD) has launched the BD Intevia 1 mL two-step disposable autoinjector, a robust platform device combining autoinjector and pre-fillable syringe in one integrated system.
BD Launches BD Intevia 1 mL two-step disposable autoinjector โ a robust...
Drug Research
Shionogi and Hsiri to develop mycobacterial disease therapies
Japanese pharmaceutical firm Shionogi has signed a licence agreement with Hsiri Therapeutics for the discovery and development of therapies for non-tuberculous mycobacterial (NTM) diseases, as well as tuberculosis (TB).
The agreement covers a technology that will complement the companyโs previous...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
















